Vivos Therapeutics, Inc. VVOS
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 0.23% | 34.44% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.23% | 34.44% | |||
| Cost of Revenue | 5.67% | 149.04% | |||
| Gross Profit | -3.47% | 2.38% | |||
| SG&A Expenses | -21.17% | 3.27% | |||
| Depreciation & Amortization | 12.33% | 2.71% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.12% | 15.19% | |||
| Operating Income | 27.06% | -3.65% | |||
| Income Before Tax | 28.74% | -11.46% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 28.74% | -11.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -39.13% | 15.00% | |||
| Net Income | 28.65% | -11.43% | |||
| EBIT | 27.06% | -3.65% | |||
| EBITDA | 29.98% | -3.72% | |||
| EPS Basic | 40.94% | 5.41% | |||
| Normalized Basic EPS | 37.66% | 5.42% | |||
| EPS Diluted | 40.94% | 5.41% | |||
| Normalized Diluted EPS | 37.66% | 5.42% | |||
| Average Basic Shares Outstanding | 20.83% | 17.79% | |||
| Average Diluted Shares Outstanding | 20.83% | 17.79% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||